Identifying targeting antibodies in an in vitro model of the human blood-brain barrier during ischemic stroke

在缺血性中风期间人血脑屏障的体外模型中识别靶向抗体

• 批准号: 10761258
• 负责人: Moriah Katt
• 金额: $ 19.7万
• 依托单位: WEST VIRGINIA UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-27 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10761258
• 关键词: Identifying; targeting; antibodies; vitro; model

Stroke is one of the leading causes of disability and death in the US. One of the contributing factors to this is the lack of FDA approved treatments for chronic stroke. Aside from tissue plasminogen activator (tPA), there are no other approved therapeutics with disease modifying effects; current therapy is entirely focused on symptom management and rehabilitation. This is in part due to the lack of understanding of the underlying mechanisms involved, as well as the difficulty of delivering therapeutics through the blood-brain barrier (BBB) and into the brain. This project aims to address both of these difficulties through the development of a human induced pluripotent stem cell (hiPSC) derived model of the BBB incorporating hiPSC derived brain microvascular endothelial like cells (BMECs), astrocytes, and neurons. Using a 3D microvessel platform ischemia will be modeled using perturbations in shear flow, oxygen concentration, and nutrient availability. The resultant phenotype of the cells will be investigated using live cell microscopy to measure permeability of fluorescent tracer molecules, as well as morphological changes in the cells. Using this model, as well as a simplified 2D model of ischemia, a library of antibodies will be screened for improved targeting and delivery to the human ischemic brain. Finally, the antibodies identified in the screen will be tested for efficacy in delivering known non-brain penetrant neuroprotectant growth factors to the ischemic brain both in the in vitro model and in a mouse model of stroke. In summary, this project will establish a human specific model of the BBB during ischemic stroke and identify antibodies that are able to specifically target and deliver therapeutics to the ischemic region of the brain.

中风是美国残疾和死亡的主要原因之一。为此的促成因素之一 是否缺乏FDA批准的慢性中风治疗方法。除了组织纤溶酶原激活剂（TPA）外， 没有其他批准的治疗疗法具有改变疾病的作用；当前的疗法完全集中 关于症状管理和康复。这部分是由于对 涉及的基本机制，以及通过血脑递送治疗剂的困难 障碍物（BBB）和大脑。该项目旨在通过 纳入BBB的人类诱导多能干细胞（HIPSC）衍生模型的开发 HIPSC衍生的脑微血管内皮细胞（BMEC），星形胶质细胞和神经元。使用3D 微血管平台缺血将使用剪切流，氧浓度，氧气中的扰动进行建模 和养分可用性。将使用活细胞显微镜研究细胞的结果表型 测量荧光示踪剂分子的渗透性，以及细胞中的形态变化。 使用此模型以及简化的缺血2D模型，将筛选一个抗体库 改善了对人类缺血大脑的靶向和递送。最后，屏幕上鉴定的抗体 将测试在将已知的非脑渗透神经保护剂生长因子传递到 体外模型和中风模型中的缺血性脑。总而言之，这个项目将 在缺血性中风期间建立BBB的人类特异性模型，并鉴定能够 特异性靶向并将治疗剂传递到大脑的缺血区域。